[go: up one dir, main page]

WO2006073982A2 - Molecule bispecifique comprenant un ligand pour une proteine de surface et un ligand pour une proteine de surface de cellules t - Google Patents

Molecule bispecifique comprenant un ligand pour une proteine de surface et un ligand pour une proteine de surface de cellules t Download PDF

Info

Publication number
WO2006073982A2
WO2006073982A2 PCT/US2005/047222 US2005047222W WO2006073982A2 WO 2006073982 A2 WO2006073982 A2 WO 2006073982A2 US 2005047222 W US2005047222 W US 2005047222W WO 2006073982 A2 WO2006073982 A2 WO 2006073982A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
molecule
cancer
aberrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/047222
Other languages
English (en)
Other versions
WO2006073982A3 (fr
Inventor
Edward D. Ball
Jie-Hua Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2006073982A2 publication Critical patent/WO2006073982A2/fr
Publication of WO2006073982A3 publication Critical patent/WO2006073982A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Definitions

  • the present invention relates to the field of treatment of neoplastic diseases and uncontrolled cell growth. More specifically, it relates to compositions and methods for treating neoplasias with bispecific molecules comprising a portion that binds to a cell-surface protein on a T-cell, and a portion that binds to a cell- surface protein on a tumor cell. Description of Related Art
  • Neoplastic diseases or cancers, are a leading cause of death in the world. Neoplastic diseases can generally be thought of as resulting from defects in cellular mechanisms regulating cell growth and division. As such, numerous molecules that are involved in cell growth or regulation of cell growth have been identified as being involved in neoplasias. Of the more common molecules that have been identified are cell surface receptors. In neoplastic cells of certain tissues, certain cell surface receptors are expressed, whereas non-neoplastic cells of the same cell type do not show expression, or show low levels of expression, of the receptor. Indeed, many cell surface receptors have been found to be expressed improperly in neoplastic cells. [004] Numerous ways of treating neoplastic diseases have been developed over the years.
  • non-surgical treatments include administering to the patient substances that are cytotoxic, and thus cause cell death ⁇ i.e., administering chemotherapeutic agents), exposure to cell-killing amounts of radiation, or both.
  • cytotoxic agents use substances that do not differentiate between normal and neoplastic cells.
  • normal, healthy cells are killed as well.
  • the substances used for treatment have become more selective, being targeted only to growing cells or cells with proteins on their surfaces that are specific for cancer cells.
  • cytotoxic agents to be used as anti-cancer compounds should specifically target the cancer cells while avoiding non-cancer cells.
  • Antibodies that are specific for cell-surface proteins that are typically expressed on cancer cells, but not normal cells, are particularly well suited for treatment of cancers.
  • While such cancer cell-specific antibodies are generally well suited for targeted treatment of cancers, often, cell surface targets that are absolutely or highly specific for cancer cells are not available. In such situations, it might be necessary to select a cell surface target that is preferentially expressed on a certain cancer cell type, and risk the potential detrimental effects of the treatment on non-cancer cells expressing the cell surface target.
  • SCLC Small cell lung cancer
  • GFP Gastrin releasing peptide
  • SCLC cells are known to produce BN-like peptides that function as autocrine growth factors to promote SCLC growth.
  • GRP receptor GRP receptor
  • SCLC small cell lung cancer
  • BN/GRP-R peptide antagonist called Antag 2
  • Antag 2 a synthetic BN/GRP-R peptide antagonist
  • the bispecific molecule was found to mediate cytotoxicity of SCLC by interferon gamma (IFN ⁇ )-activated human monocytes in conjunction with chemotherapy.
  • IFN ⁇ interferon gamma
  • Cytotoxic T lymphocytes are potent immune effector cells. They can be activated through their T-cell receptor (TCR) to effectively kill a target cell. Antigen recognition is mediated by either the alpha/beta chain, or gamma/delta chain of the TCR. The alpha/beta chain forms a heterodimer that is closely associated with a cluster of transmembrane peptides to form a CD3 complex on the T cell surface. Li patients with advanced cancer, the host T cells are functionally suppressed and unable to mount an effective attack on cancer cells. There are several common mechanisms to explain why cancer cells escape the host immune system, including lack of the recognition antigens on the cancer cells and inadequate activation of immune trigger molecules on host immune effector cells.
  • OKT3 is an anti-CD3 monoclonal antibody that is specific for TCR.
  • BsAb bispecific antibodies
  • a BsAb, OKT3xTrastuzumab (anti-CD3xanti-HER2) has been shown in preclinical studies to effectively mediate the killing of HER2-positive breast cancer cells.
  • a phase I trial has been planned for patients with stage IV metastatic breast cancer.
  • a recombinant single-chain BsAb, anti-CD3xanti-CD19 has been shown to effectively activate autologous T cells from patients with advanced B cell lymphoma or leukemia, and effectively kill the autologous B cells at a low effector to target cell ratio.
  • siRNA small-interfering RNAs
  • shRNA short hairpin RNA
  • the present invention addresses the need in the art by providing new therapeutic molecules, compositions comprising those molecules, methods of treating neoplasias and other disease, disorders, and infections using those molecules, and methods of diagnosing neoplasias or the predisposition to neoplasias, other diseases and disorders, and infections using those molecules.
  • the therapeutic molecules comprise at least one portion that binds to a cell-surface protein of a target cell, and at least one portion that binds to a cell-surface protein of a T-cell of the patient.
  • the therapeutic molecule is an immunotherapeutic bispecific molecule comprising an antigen-binding region of an anti-CD3 monoclonal antibody (or an equivalent structure created by known techniques) and an antagonist for a cell- surface receptor on a tumor cell.
  • the immunotherapeutic molecule comprises an anti-CD3 monoclonal antibody and the bombesin (BN) antagonist (Antag2).
  • BN bombesin
  • the exemplary bi-specific molecule (BsMoI) is capable of binding, through its antibody portion, to CD3 present on T cells, and to SCLC or other cancer cells expressing BN/GRP-R, thus bridging the two cells.
  • Binding of a BsMoI according to the invention can effectively activate T cells and induce growth inhibition of cancer cells at a low E:T ratio. Accordingly, the BsMoI of the invention can be used in therapy of cancer.
  • the BsMoI targets the GRP-R on the tumor cell surface and a cytotoxic trigger molecule on immune effector cells to activate antibody-dependent, cell-mediated cytotoxicity, hi experiments in vitro, tumor cell growth inhibition of 74% was observed when BsMoI was present, compared with 33% inhibition when tumor cells were cultured with only 0KT3, and 4% inhibition was observed when no antibody was present. If tumor cells were pre- incubated with free antagonist peptide, the BsMoI targeted cytotoxicity was blocked. So, the BsMoI interrupts the BN/GRP binding to BN/GRP-R and also induces a polyclonal T cell activation and specific targeting of tumor cells which results in tumor cell lysis and apoptosis.
  • the present invention provides a molecule that can target T-cells to aberrant cells in a patient (also referred to herein as a "subject") and cause the death of those aberrant cells.
  • this molecule is referred to as a "bi-specific" molecule, without limitation to the actual number of binding sites available on any particular molecule.
  • the function of the molecule is provided, at least in part, by the presence of at least two distinct regions or portions: one region having a three-dimensional structure that is capable of binding to a cell-surface protein on the surface of a target cell (e.g., a cancer cell), the other region having a three-dimensional structure that is capable of binding to a cell-surface protein on the surface of a T-cell. Binding of both regions to their respective binding partners (i.e., proteins on the respective cells) causes the T-cell to come into close proximity to the target cell, and ultimately cause the death of the target cell.
  • the invention provides compositions comprising the bi- specific molecule of the invention.
  • compositions comprise the bi- specific molecule of the invention and at least one other substance that is compatible with the bi-specific molecule, such as a solvent, a carrier, or a cell
  • the composition is a pharmaceutical composition that comprises the bi- specific molecule of the invention and at least one pharmaceutically acceptable or biologically tolerable substance.
  • the invention provides nucleic acids encoding at least part of a bi-specific molecule of the invention.
  • the bi-specific molecule comprises an amino acid sequence that may be encoded by a nucleic acid.
  • This aspect of the invention includes nucleic acids comprising not only the sequence encoding at least a portion of a bi- specific molecule, but other sequences that are useful in expressing and/or maintaining nucleic acids in a cell. Thus, it includes vectors for expressing or maintaining the coding sequences. Compositions comprising the nucleic acids of the invention are provided as well.
  • the methods comprise expressing a nucleic acid encoding at least a portion of a bi-specific molecule of the invention. Where the bi-specific molecule is entirely coded by a nucleic acid, the method does not require any further steps. Where the bi-specific molecule comprises non-proteinaceous material, the method further comprises associating the proteinaceous portion(s) with the non- proteinaceous portion(s) through covalent, ionic, or hydrophobic bonding. In embodiments, the methods of making include purifying, at least to some extent, the bi-specific molecule away from other substances that are present in the environment where the bi-specific molecule is found.
  • the invention provides cells.
  • the cells can comprise the bi-specific molecule or a portion thereof.
  • the cells can comprise one or more nucleic acids that encode at least a portion of the bi-specific molecule of the invention.
  • the cells can be useful for expressing the bi-specific molecule or at least a portion of it. They can also be useful for therapy for one or more neoplasias, diseases, disorders, or infections.
  • the cells are T-cells comprising a bi- specific molecule associated with the cell by way of attachment to a cell-surface protein.
  • the present invention provides methods of treating a patient suffering from a neoplasia or other disease or disorder, or an infection.
  • the method comprises administering at least one bi-specific molecule according to the invention, at least one nucleic acid according to the invention, or at least one cell according to the invention, to a patient in need thereof in an amount sufficient to inhibit the growth or kill at least one neoplastic cell, at least one cell of a disease or disorder, or at least one infected cell.
  • the step of administering is repeated two or more times.
  • the invention provides for use of a bi-specific molecule of the invention in the production of a therapeutic or pharmaceutical composition.
  • nucleic acid encoding at least a portion of a bi-specific molecule of the invention in the production of a therapeutic or pharmaceutical composition. It further provides for use of a cell of the invention in the production of a therapeutic or pharmaceutical composition.
  • the invention provides for use of a bi-specific molecule of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection.
  • the invention provides for use of a nucleic acid of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection.
  • the invention provides for use of a cell of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection.
  • the present invention provides methods of diagnosing neoplasias or a predisposition to neoplasias, or other diseases or disorders or infections.
  • the methods of diagnosing are methods of detecting the presence of a cell-surface protein on a target cell.
  • the methods comprise exposing a cell that is or is suspected of being a neoplastic cell, a cell of another disease or disorder, or an infected cell to a bi-specific molecule of the invention and determining whether the bi-specific molecule has bound to the cell.
  • the method further comprises determining whether the molecule causes inhibition of cell growth or cell death.
  • the invention provides at least one container that contains a bi-specific molecule of the invention, a nucleic acid of the invention, and/or a cell of the invention.
  • the container can be any container, but in embodiments, it is a vial or the like, such as those used to contain pharmaceutically active substances.
  • Figure 1 depicts the relevant amino acid sequences of bombesin, gastrin- releasing peptide, and the Antag2 peptide of the present invention.
  • Figure 2 depicts a schema of the chemical conjugation of the BsMoI.
  • Figure 3 depicts general protocol for preparing and testing T cells for response to various treatments.
  • Figure 4 shows the results of flow cytometry assays of the BsMoI of the invention binding to four different SCLC cell lines, H345 (Figure 4A), H69 ( Figure 4B), DMS273 (Figure 4C), and SHP77 (Figure 4D).
  • Figure 5 shows flow cytometry analysis of the BsMoI binding to lymphocytes (Figure 5A) and monocytes ( Figure 5B).
  • Figure 6 shows flow cytometry analysis of the specificity of BsMoI binding to SCLC cell line HE34 after treatment with bombesin (Figure 6A), Antag2 (Figure 6B), and angiotensin (Figure 6C).
  • Figure 7 shows the inhibition of growth of cells after treatment with various compounds.
  • Figure 8 shows the growth inhibition of DMS273 cells by T cells from four normal donors at an E:T ratio of 2.5:1.
  • Figure 9 shows analyses of tumor cell growth inhibition and the dose- response effect of BsMoI.
  • Figure 10 shows the effect of IL-2 on thymidine incorporation (Figure 10A) and the effect of increasing concentration on thymidine incorporation ( Figure 10B).
  • Figures 1 IA and 1 IB show flow cytometry data relating to annexin V and PI expression in SCLC cells.
  • Figure 12 shows data relating to apoptosis and necrosis of cells exposed to BsMoI.
  • Panel A DMS273 cells;
  • Panel B SHP77 cells;
  • Panel C H345 cells.
  • Figure 13 depicts data relating to release of interferon gamma by T cells in culture with various SCLC cells.
  • Figure 14 depicts Western blots of various cell proteins implicated in apoptosis after exposure of cells to BsMoI.
  • Panel A shows Bcl-2 family protein expression in 4 SCLC cell lines.
  • Panel B shows the expression of anti-apoptotic protein Bcl-2 and pro-apoptotic proteins Bax and Bak after ADCC.
  • Panel C shows the changes of Bcl-2 expression, Bad/p-Bad ratio during ADCC in H345 cells.
  • Figure 15 depicts Western blots of various cell proteins implicated in apoptosis after exposure of cells to BsMoI.
  • bi-specific molecules also referred to herein as "BsMoI" that comprise one or no sequences from antibodies.
  • BsMoI are effective at targeting neoplastic cells and other cells exhibiting signature proteins on their cell surfaces
  • one domain of the BsMoI is specific for a T cell receptor while the other is specific for a protein on the surface of a neoplastic cell
  • a bi-specific molecule targeting BN/GRP-R and immune trigger molecules can mediate an effective destruction of SCLC cells
  • a combined chemotherapy and BsMol-targeted immunotherapy significantly increases the destruction of SCLC cells in vitro.
  • the present invention uses the BsMoI to recruit cytotoxic T cells to SCLC cells, either in vitro or in vivo, to inhibit the growth of the cells.
  • Treatment of the cells can further comprise combining this targeted immunotherapy with an anti- Bcl-2 approach to further enhance the specific SCLC destruction.
  • the present invention provides a molecule that can target T cells to aberrant cells in a patient (also referred to herein as a "subject") and cause the death of those aberrant cells.
  • this molecule is referred to as a "bi-specific" molecule, without limitation to the actual number of binding sites available on any particular molecule.
  • the function of the molecule is provided, at least in part, by the presence of at least two distinct regions or portions: one region having a three-dimensional structure that is capable of binding to a cell-surface protein on the surface of a target cell ⁇ e.g., a cancer cell), the other region having a three-dimensional structure that is capable of binding to a cell-surface protein on the surface of a T cell. Binding of both regions to their respective binding partners ⁇ e.g., to proteins on the respective cells) causes the T cell to come into close proximity to the target cell, and ultimately causes cessation of growth or, preferably, the death of the target aberrant cell.
  • the bi-specific molecule of the invention comprises at least one portion that binds to a molecule on the surface of a T cell.
  • Many molecules that appear on the surface of T cells are known, and any of these molecules may be used as targets for binding of the bi-specific molecule of the invention.
  • cell surface receptors such as TCR, CD2, CD3, CD4, CD8, and CD56 are present on the surface of T cells.
  • binding of the bi-specific molecule to the T cell surface molecule causes activation of the T cell.
  • T cell surface molecules that are targeted may simply be selected based on their presence and potential involvement in the cell killing process. In other words, one may select any molecule on the surface of a T cell, because the primary goal of the bi-specific molecule is to bring the T cell into close proximity to the aberrant cell that is targeted for destruction. It is preferred however, that the T cell surface molecule is selected such that it not only functions in binding of the bi-specific molecule, but, when bound by the bi-specific molecule, also produces at least one substance that causes or participates in the destruction of the target aberrant cell.
  • the molecule on the surface of the T cell that is the target of the bi-specific molecule can be any molecule.
  • it may be a protein, a lipid, a lipoprotein, a glycoprotein, a sugar, a polysaccharide, any other simple or complex molecule known to be present on the surface of cells or viruses, or a combination of two or more of these.
  • the number of molecules that are present on the T cell surface the molecule may be present as a single copy or multiple copies, or may be present only on a sub-set of T cells that are present in a particular subject.
  • the molecule is a protein or comprises a peptide portion.
  • the bi-specific molecule of the invention comprises at least one portion that binds to a target aberrant cell.
  • aberrant cells express on their surfaces complements of molecules, which are generally known and studied in the art. Certain of these molecules, or collections of molecules, are either specific for each different aberrant cell, or are semi-specific (i.e., are present on the target cell and only certain other cells). Any of these molecules may be targeted by the bi-specific molecule of the invention.
  • the bi-specific molecule may comprise a portion that binds to any of the following cell surface proteins or members of the following cell surface protein families: the ErbB family of protein tyrosine kinases (e.g., erbBl/HER- 1/EGFR, erbB2/HER-2/neu, erbB3 and erbB4), which are overexpressed in some tumor cells and contribute to cell proliferation, regulation of apoptotic cell death, angiogenesis, and metastatic spread; epithelial growth factor receptor (EGFR), which is implicated in breast, non small cell lung, colorectal, bladder, prostate, ovarian, and pancreatic cancers; the HER family of proteins, which are involved in breast and endometrial cancers (e.g, HER2, HER2/neu) - representative ligands include, but are not limited to, heregulin, neuregulin, epiregulin and biregulin; vascular endothelial growth factor (VEGF), which is
  • Certain non-limiting ligands for these receptors include the CCR7 ligands CCL19/ELC and CCL21/SLC, and the CXCR5 ligand CXCLl 3/BCA-l.
  • targets for melanoma can be the gangliosides GM2 and GD3.
  • the CD4 receptor on HIV infected cells may serve as a target for aberrant cells.
  • the bi-specific molecule may also bind to the following exemplary molecules, which are known to be present on certain neoplastic or infected cells: CXCR4 receptor on small cell lung cancer (involving the chemokine stromal derived factor- 1(SDF-I /CXCLl 2) ligand); members of the ERK pathway, such as RET in thyroid cancer; proteins expressed in cells infected with the Hepatitis C virus, such as CD81 tetraspanin (TAPA-I) and the scavenger receptor SR-BI, which binds to integrin beta 1 and integrin alpha 3, among other things; the DC-SIGN (dendritic cell- specific ICAM-grabbing non-integrin, where ICAM is the intercellular adhesion molecule), which is a mannose-specific C-type lectin expressed by dendritic cells; and CCR5 and CXCR4, which have been shown to be co-receptors for HIV infection (ligands include SDF-I
  • the bi-specific molecule of the invention comprises at least one portion that can bind to a molecule, including those well-known proteins discussed above and known in the art, present on the surface of an aberrant cell, such as a neoplastic cell or a cell infected with a virus or intracellular parasite.
  • a bi-specific molecule of the invention may have a portion that binds to a cell surface protein that, when activated, initiates an apoptosis pathway.
  • a bi-specific molecule of the invention may have a portion that binds to a cell surface protein that causes the cell to enter a senescence phase, in which cell growth is halted, but the cell does not necessarily begin a process of self-destruction.
  • Many such proteins are known in the art, as are ligands for them, and any of these proteins and ligands can be used as part of a bi-specific molecule of the invention.
  • one or more of the active portions or regions comprise a 3 -dimensional structure that is identical to a ligand for a cell-surface molecule on a T cell or on a target aberrant cell.
  • one or more of the active portions has a 3-dimensional structure that is similar, but not exactly the same, as a ligand for a cell-surface molecule on a T cell or a target aberrant cell, hi such a situation, the ligand can be an antagonist of the true ligand, and can bind to the cell surface molecule, but not cause the same biological effect. Alternatively, it can bind equally well or better, and result in an equally good or better response from the cell.
  • the bi-specific molecule of the invention can have three or more active portions. That is, the terminology "bi-specific” is not meant to limit the molecule of the invention to only two portions that can bind cells. Rather, the bi-specific molecule can have two or more portions that bind to cells of interest. Typically, the bi-specific molecule has at least one portion that binds to a T cell, and at least one other portion that binds to an aberrant cell of interest.
  • the bi-specific molecule has one portion that binds to a T cell and one portion that binds to an aberrant cell, hi other embodiments, the bi-specific molecule has one portion that binds to a T cell and two or more portions that bind to a target aberrant cell. In yet other embodiments, the bi-specific molecule has one portion that binds to an aberrant cell and two or more portions that bind to a T cell. In yet further embodiments, the bi- specific molecule comprises two or more portions that bind to a T cell and two or more portions that bind to an aberrant cell. Any number of combinations of active portions can be envisioned, and all of those combinations are included within the scope of the present invention.
  • the portions may be specific for the same cell surface molecule, or may be specific for different ones.
  • the specificity of the bi-specific molecule may be increased. For example, where a tumor cell expresses a complement of signature proteins on its surface, but one or more of those proteins is also expressed on other, non-tumor cells, inclusion of two or more portions of the bi-specific molecule that are individually specific for each of the proteins on the tumor cell, improved binding to the tumor cell might be obtained, and an increased effectiveness might be achieved.
  • an aberrant cell expresses two different proteins on its surface, each of which is involved in a distinct cellular process that could be taken advantage of for inhibition of cell growth or for cell killing
  • a bi-specific molecule comprising ligands for both of those cell surface proteins can be designed and used.
  • the two or more active portions are linked to each other.
  • Linkage can be through any suitable association, such as through covalent, ionic, or hydrophobic bonding.
  • the main concern in selecting the type of association is whether the molecule will remain intact throughout the time in which it is expected to be active. That is, for the bi-specific molecule to function as envisioned, the two (or more) active portions should be sufficiently well linked that they do not dissociate to an unacceptable extent under the conditions in which they are to be used. Thus, it is preferred that the active portions be covalently linked.
  • Linking of two or more molecules, whether they be peptides, sugars, nucleic acids, or any other organic or inorganic molecules to form the bi-specific molecule of the invention can be through any suitable techniques.
  • a number of suitable techniques for linking two or more such molecules are well known in the arts of chemistry and biochemistry, and need not be detailed here. It is now a routine matter for those of skill in the art to link any number of different types of molecules together to achieve a product.
  • the bi-specific molecule comprises of two or more peptide active portions
  • the active portions may be encoded as a single chain from a nucleic acid that has been engineered to express both portions.
  • the entire sequence may be chemically synthesized.
  • the two portions may be separately synthesized (e.g., chemically or by expression of two separate nucleic acids), then fused. Where more than two peptide portions are used, a branching structure may be used according to known principles of protein synthesis.
  • the active portion may be composed of only those structural portions that are required to form the proper 3-dimensional features for activity, or may comprise additional atoms/moieties/structures, which do not play any or any significant role in forming or maintaining the proper 3-dimensional structure.
  • the molecule may consist of the active portions, linked together, or may comprise the active portions and other portions.
  • the active portions of the bi-specific molecule may be fused directly to each other (or to at least one other active portion of the molecule), or may be linked via a linker, stuffer, etc.
  • the linker may be provided to better ensure proper folding of protein sequences, to provide sufficient distance between one or more active region and one or more other active region, or to provide flexibility to the molecule, or for any other reason that appears to be important to those practicing the invention.
  • the size and structure of the linker is not critical to practice of the invention, although a linker should be chosen that does not interfere with the function of the active regions.
  • the bi-specific molecule of the invention comprises an antibody framework, onto which an SCLC-specific ligand is grafted.
  • the bi-specific molecule comprises an antibody, or a portion of an antibody (e.g, the Fc region, Fab, Fab', single chain, CDR).
  • the antibody or fragment may be from any source, including, but not limited to, humans, other mammals (e.g., mouse, rat, monkey, rabbit).
  • the antibody may be a polyclonal antibody, but is preferably a monoclonal antibody.
  • the antibody or fragment may also be a modified antibody, such as a humanized antibody, a chimeric antibody, or a fusion antibody, hi certain embodiments, an antibody framework is used, where the antigen binding region has been engineered to contain a particular 3-dimensional structure that mimics a ligand or, more preferably, an antagonist of a ligand.
  • the aberrant cell can be any cell that is abnormal in any way.
  • it can be a cell that has an abnormal growth profile (e.g., uncontrolled growth, as seen in neoplastic cells).
  • It also can be a cell that expresses one or more proteins that are not normally expressed by cells of its type, or that expresses one or more proteins encoded by a virus or intracellular parasite, or that are expressed by the cell as a result of infection by a virus or intracellular parasite (including certain bacteria that reproduce within cells).
  • It can also be a cell that overexpresses a protein that is normally found in the cell, such as on the surface of the cell.
  • an aberrant cell can be a neoplastic cell, such as a cell from a benign tumor or a cell from a malignant tumor. It can be a cell that is infected with a virus, such as HIV, HCV, HBV, influenza, or papilloma virus. It further can be a cell that is infected with an intracellular parasite, such as a mycobacterium or any of the various single-celled eukaryotic intracellular parasites.
  • a virus such as HIV, HCV, HBV, influenza, or papilloma virus.
  • an intracellular parasite such as a mycobacterium or any of the various single-celled eukaryotic intracellular parasites.
  • neoplastic cell is included among the aberrant cells of the invention, including, but not limited to, lung cancer cells, breast cancer cells, prostate cancer cells, colorectal cancer cells or other cancer cells of the gastrointestinal tract, kidney cancer cells, hepatocarcinoma cells, brain cancer cells, pancreas tumor cells, and esophageal cancer cells.
  • Other non-limiting examples of cells are uterine cancer cells, cervical cancer cells, endometrium cells, melanoma cells, renal cancer cells, and Kaposi's sarcoma cells, hi addition, an exemplary cell is any cells that expresses GRP-R on its cell surface.
  • the invention provides compositions comprising the bi- specific molecule of the invention.
  • the compositions comprise the bi- specific molecule of the invention and at least one other substance that is compatible with the bi-specific molecule, such as a solvent, a carrier, or a cell.
  • the composition comprises two or more different bi-specific molecules.
  • the composition is a pharmaceutical composition that comprises the bi-specific molecule of the invention and at least one pharmaceutically acceptable or biologically tolerable substance.
  • the substance can be any of the well known substances present in pharmaceuticals, including, but not limited to, water or an aqueous liquid (including saline and its various medicinal/pharmaceutical forms), one or more fillers, binders, colorants, stabilizers, buffers, or other substances that stabilize or promote effective uptake of pharmaceutically active compounds.
  • the substance may also be a sugar or other substance that is effective in protecting compounds during lyophilization.
  • any of the well known reagents and other substances that are used in cell culture may be included in compositions according to the invention.
  • the composition is a pharmaceutical. Accordingly, the composition may be a capsule, pill, or any other dosage form that can be ingested or taken in through a mucous membrane.
  • composition may also be an injectable or infusible liquid, or a solid suitable for adding to a liquid to make an injectable or infusible liquid composition.
  • Any of the various compositions known as useful for delivering pharmaceutically active substances to a patient are envisioned as part of this invention.
  • the invention provides nucleic acids encoding at least part of a bi-specific molecule of the invention. As discussed above, the invention encompasses bi-specific molecules that consist of or comprise amino acid sequences.
  • amino acid sequences can be encoded by a nucleic acid of the invention, hi embodiments where the bi-specific molecule comprises two or more amino acid sequences fused together, the entire fusion sequence may be encoded by a nucleic acid of the invention, hi particular embodiments, the invention provides nucleic acids that encode an antibody or portion thereof (e.g., Fc portion, single chain antibody, etc.).
  • This aspect of the invention includes nucleic acids comprising not only the sequence encoding at least a portion of a bi-specific molecule, but other sequences that are useful in expressing and/or maintaining nucleic acids in a cell.
  • compositions comprising the nucleic acids of the invention are provided as well. These compositions typically comprise the nucleic acid of the invention along with one or more other substance, including, but not limited to one or more enzyme or reagent useful for expressing a polypeptide from a nucleic acid. Thus, the compositions may include any of the numerous polymerases available commercially. It can also comprise any substance that is typically used in storing nucleic acids in a stable manner, such as in a freeze-dried state.
  • Methods of making the bi-specific molecule of the invention comprise combining two or more substances that comprise active regions, where at least one of the active regions is capable of binding to a molecule on the surface of a T cell and at least one other of the active regions is capable of binding to a molecule on the surface of an aberrant cell of interest.
  • Cell surface molecules for each type of cell are known in the art, and any such molecule may be selected as a target.
  • the act of combining can be any action that results in two or more active regions becoming associated with each other.
  • it can comprise mixing the two or more substances under conditions that permit covalent, ionic, or hydrophobic bonding, hi embodiments, it comprises covalently bonding the substances.
  • combining can be accomplished in two or more steps, or in a single step.
  • bonding can be accomplished in two or more steps or in a single step. For example, where a bi-specific molecule comprising three active regions is made, one may combine two of the three together, bond them together, add the third region to the fusion product, and bond the third region to create a fusion product comprising all three regions.
  • portion A bound to portion B which is bound to portion C
  • portion A bound to portion C which is bound to portion B
  • portion A bound to portion B and C etc.
  • the bi-specific molecule comprises an amino acid portion.
  • the methods can comprise expressing a nucleic acid encoding at least a portion of the bi-specific molecule of the invention.
  • the method might not require any further steps. However, it might require further steps, including permitting the expressed protein to fold into a proper three dimensional shape.
  • the entire bi-specific molecule may be expressed as a single-chain protein from a single nucleic acid.
  • two or more different amino acid sequences may be part of the bi-specific molecule, and they may be expressed independently of each other, then associated with each other through covalent, ionic, or hydrophobic bonding.
  • the method further comprises associating the two or more portions with each other.
  • one or more of the portions are proteinaceous portions, and these are associated with the non- proteinaceous portion(s) through covalent, ionic, or hydrophobic bonding.
  • the methods of making include purifying, at least to some extent, the bi-specific molecule away from other substances that are present in the environment where the bi-specific molecule is found.
  • the method can further comprise making a composition, such as a pharmaceutical composition, comprising the bi-specific molecule. In such methods, at least one bi-specific molecule is combined with at least one other bi-specific molecule or one or more other substances that are pharmaceutically acceptable or biologically tolerable.
  • the invention provides cells.
  • the cells can comprise one or more bi-specific molecules or portions thereof, or one or more nucleic acids that encode at least a portion of at least one bi-specific molecule of the invention.
  • the cells may comprise the bi-specific molecules or nucleic acids internally or as one or more molecules that are at least partially exposed to the exterior of the cell.
  • one or more bi-specific molecules of the invention are attached to the exterior of a cell, such as by way of ionic or hydrophobic interactions with one or more substances on the surface of the cell.
  • Cells of the invention have multiple uses.
  • the cells can comprise nucleic acids according to the invention and can be useful for expressing the bi-specific molecule or at least a portion of it.
  • the cells can be used in a method of making the bi-specific molecule of the invention.
  • a single cell expresses multiple bi-specific molecules of the invention.
  • Cells of the invention can further be useful for research to determine various characteristics of bi-specific molecules of the invention. For example, they can be used to identify particular bi-specific molecules having high specificity, high affinity for particular aberrant cells or T cells, and/or high level of activation of T cells or activation of apoptosis pathways in target aberrant cells, among other things.
  • Cells of the invention can also be useful for therapy for one or more neoplasias, diseases, disorders, or infections.
  • cells of the invention can be produced in vivo by administration of one or more bi-specific molecules of the invention to a patient, with the result being an activated T cell linked via the bi- specific molecule to a target aberrant cell.
  • cells of the invention can be made ex vivo by loading one or more bi-specific molecules of the invention onto T cells, then re-introducing the loaded T cells into the patient to provide an activated T cell that can bind to a target aberrant cell of interest.
  • the cells are T-cells comprising a bi-specific molecule associated with the cell by way of attachment to a cell-surface protein
  • the cell is a target aberrant cell comprising one or more bi- specific molecules associated with the cell by way of attachment to a cell-surface protein.
  • the present invention provides methods of treating a patient suffering from a neoplasia or other disease or disorder, or an infection, hi general, the method comprises administering at least one bi-specific molecule according to the invention, at least one nucleic acid according to the invention, or at least one cell according to the invention, to a patient in need thereof in an amount sufficient to inhibit the growth or kill at least one neoplastic cell, at least one cell of a disease or disorder, or at least one infected cell (i.e., an aberrant cell).
  • the methods provide a treatment for the patient.
  • the methods provide a therapy for the patient by reducing or halting the growth of at least one aberrant cell in the patient's body.
  • the methods result in killing of at least one aberrant cell in the patient's body.
  • the method results in reduction in the growth rate of at least one tumor (including non- solid tumors), as compared to the growth rate seen prior to treatment or as compared to an equivalent subject who did not receive the treatment.
  • the treatment results in inhibition of tumor growth, whereas in others, it results in a reduction in tumor size or a reduction in the number of neoplastic cells.
  • the method results in elimination of all or essentially all of the neoplastic cells.
  • the method of treating can comprise a treatment regimen. Accordingly, the method can comprise repeating the step of administering one or more times. Furthermore, the step of administering can comprise administering one or more other bi-specific molecules or one or more other substances that can have a treating effect on the target aberrant cells. Multiple rounds of treatment, each with or some without a bi-specific molecule of the invention, may be performed. Treatment regimens can include dosing with chemotherapeutic agents.
  • Administering can be accomplished by any suitable method known in the art. In general, administering is performed on a subject in need of treatment for an aberrant cell, such as a neoplastic cell or an infected cell. The amounts administered are amounts sufficient to achieve a therapeutic effect, such as to cause an aberrant cell to cease growing or to die. Numerous techniques for administering substances systemically to the blood system of humans and animals is known, and any one can be used. For example, administration can be through bolus injection of the substance into a vein or artery, administration over minutes or hours by way of intravenous infusion, or oral administration byway of liquid or solid (e.g., tablet, capsule, powder).
  • liquid or solid e.g., tablet, capsule, powder
  • chemotherapeutic substances such as the bi-specific molecule of the present invention, to be administered to patients are well known to those of skill in the art, and appropriate amounts to be administered in accordance with the present invention can be determined without excessive experimentation. As a general rule, chemotherapeutic substances can be administered to subjects in therapeutically effective amounts.
  • Those amounts generally range from about 0.01 g/m 2 of body area to about 30 g/m 2 body area, and can be administered over any amount of time, such as a short period (about 6 hours or less) or a much longer period (about 96 hours or longer) through continuous infusion.
  • Dosing regimens can include considerably longer times, such as two weeks, one month, or more.
  • doses of the chemotherapeutic substance(s) can be relatively short (e.g., the entire dose being administered in one to several hours), and the doses repeated at regular intervals, such as daily, once weekly, twice weekly, or at other intervals.
  • chemotherapeutic dosing regimens are known to those of skill in the art, and any suitable regimen can be used.
  • treatment comprises administering one or more bi-specific molecules based on an antibody frame
  • it will generally be administered in an amount from about 0.1 mg/m 2 of the patient's body area to about 15.0 mg/m 2 body area.
  • the injections can be administered at days 1 and 14 of a treatment regimen.
  • one or more bi-specific molecules can be administered in a regimen comprising two treatment cycles, hi the first cycle, the molecule can be administered at exactly or about 10 - 20 mg/m 2 daily for 4 days, hi the second cycle, the molecule can again be administered at exactly or about 10 - 20 mg/m 2 at 10-12 days after completion of the first cycle.
  • the method of treating is a method of treating a patient suffering from a neoplasia.
  • the method is preferably a therapeutic method that results in cessation of proliferation of aberrant cells, reduction in the number of aberrant cells in the patient, or elimination of the aberrant cells in the patient. It can thus be a method of treating cancer.
  • it is a method of treating small cell lung cancer (SCLC).
  • SCLC small cell lung cancer
  • it is a method of treating breast cancer, a method of treating prostate cancer, a method of treating colorectal cancer, a method of treating non-small cell lung cancer, or a method of treating two or more of these.
  • the invention provides a method of treating a neoplasia, including a malignant tumor and a benign tumor.
  • the neoplasia treated can be a solid tumor or a non-solid tumor.
  • the invention further provides for use of a bi-specific molecule of the invention in the production of a therapeutic or pharmaceutical composition. It also provides for use of a nucleic acid encoding at least a portion of a bi-specific molecule of the invention in the production of a therapeutic or pharmaceutical composition. It further provides for use of a cell of the invention in the production of a therapeutic or pharmaceutical composition. Likewise, the invention provides for use of a bi-specific molecule of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection. Thus, the invention provides for use of a nucleic acid of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection. Accordingly, the invention provides for use of a cell of the invention in treating a subject suffering from a neoplasia or other disease or disorder or an infection.
  • the present invention provides methods of diagnosing neoplasias or a predisposition to neoplasias, or other diseases or disorders or infections.
  • the methods of diagnosing are methods of detecting the presence of a cell-surface protein on a target cell.
  • the methods comprise exposing a cell that is suspected of being an aberrant cell to a bi- specific molecule of the invention and detemrming whether the bi-specific molecule has bound to the cell. Binding of the bi-specific molecule to the cell indicates that the cell is an aberrant cell of interest. Lack of binding indicates that it is not.
  • the method can comprise control reactions to confirm that all steps in the method, and all reagents being used, worked as expected. Design of such controls is well within the skill level of those of skill in the art, and need not be detailed here.
  • the method further comprises determining the biological effects of binding of the bi-specific molecule to the target cell. For example, the method can comprise determining whether the molecule causes inhibition of cell growth or cell death. Assays for the various effects of interest are well known to those of skill in the art, and need not be detailed herein.
  • the methods of diagnosing comprise exposing cells that express or are suspected of expressing the cell-surface receptor (e.g., BN/GRP-R) to the molecule of the invention in the presence of at least one T cell, and determining whether the cells show inhibition of growth as compared to a control group not exposed to the molecule, to T cells, or both. Inhibition of growth of cells in the presence of the molecule of the invention and T cells indicates the presence of cancer cells in the sample tested.
  • the cancer is SCLC, breast cancer, prostate cancer, a cancer of the GI tract, or a combination of two or more of these.
  • the invention provides at least one container that contains a bi-specific molecule of the invention, a nucleic acid of the invention, and/or a cell of the invention.
  • the container can be any container, but in embodiments, it is a vial or the like, such as those used to contain pharmaceutically active substances.
  • BsMoI bi-specific molecule
  • mAb monoclonal antibody
  • Antag2 synthetic BN/GRP antagonist
  • the BsMoI also referred to herein as OKT3xAntag2
  • TCR T cell receptor
  • GRP Gastrin-releasing peptide
  • SCLC small cell lung cancer
  • FIG. 1 The sequence of the Antag2 peptide is shown in Figure 1 as SEQ ID NO:3, in which bold amino acids indicate amino acids conserved among the Antag2 and the GRP (SEQ ID NO:1) and BN (SEQ ID NO:2) peptides.
  • Figure 2 depicts the scheme for generating the BsMoI that is used throughout the Examples below. Conjugation of the two molecules making up the BsMoI, OKT3 and Antag2, followed the protocol of Zhou et al., Clinical Cancer Research 9:4953-4960, 2003.
  • OKT3 an anti-CD3 monoclonal antibody from Ortho Biotech, Raritan, NJ
  • SPDP N-succinimidyl 3-[2-py ridyldithio] propionate; Pierce, Rockford, IL
  • Unreacted SPDP was removed by dialysis.
  • Antag2 was then mixed with the activated antibody at a 10:1 molar ratio overnight. Then, free Antag2 was removed by size- exclusion dialysis.
  • a BN antagonist (Cys -D-Phe , Leu-NHEt , des-Met 14 )BN(5_i4), was custom-synthesized by BACHEM Inc (Torrance, CA). Thus, it contains a free sulfhydryl group at the N-terminus of the peptide.
  • the insertion of a D-amino acid, Phe, into position 6 and a desMet 14 analogue at the C-terminus increases the binding affinity as well as the potency by more than 20-fold.
  • a cysteine added at the N- terminus creates a free sulfhydryl group for chemical reaction without interfering with its biological activity.
  • This antagonist is depicted in the figure, but was not conjugated to the antibody for use in the experiments described below. Rather, it is included in the figure to show an alternative antagonist that can be used in accordance with the invention.
  • BsMoI The resulting bi-specific molecule, referred to herein as BsMoI, had anti- SCLC activity, m summary, the BsMoI, OKT3xAntag2, significantly inhibited the growth of SCLC cells mediated by T cells in vitro and in vivo.
  • the BsMoI activates T cells by increasing IFN ⁇ production, and induces target cell apoptosis by activation of caspase 3 (CASP3) and cleavage of poly-ADP ribose polymerase (PARP).
  • CASP3 caspase 3
  • PARP poly-ADP ribose polymerase
  • the cells were maintained in serum-free RPMI1640 medium containing IxIO "8 M hydrocortisone, 5ug/ml of insulin, lOug/ml of transferrin, IxIO "8 M ⁇ -estradiol, and 3xlO- s M selenium (HITES medium).
  • exemplary cells grown in this media were four human SCLC cell lines, H345, H69, SHP77, and DMS273. All chemical reagents were purchased from Sigma Chemical Company (St. Louis, MI). H345 was purchased from the American Type Culture Collection (Rockville, Maryland).
  • DMS273 was established from the pleural fluid of a patient with SCLC in 1980 at Dartmouth Medical School, and has been used in our laboratory for a variety of in vitro and in vivo studies (Zhou JH, et al., "Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer", Clin Cancer Res 9:4953-60, 2003; Pettengill OS, et al., "Animal model for small cell carcinoma of the lung effect of immunosuppression and sex of mouse on tumor growth in nude athymic mice", Expl Cell Biol 48:279-97, 1980).
  • T Lymphocytes [091] Many of the following Examples utilize T cells for analysis of the activities of the exemplary BsMoI. T cells were obtained for each experiment as follows: Buffy-coat cells from unselected healthy donors were obtained from the San Diego Blood Bank. Peripheral blood mononuclear cells (PBMC) were separated by FicoU-Hypaque density centrifugation. Non-adherent cells were collected after incubating the PBMC in DME medium containing 0.2% BSA at 37°C, 5% CO 2 for 2h. The lymphocytes were cultured in RPMI 1640 medium containing 10% FCS and 100U/ml of DL-2 (Chiron Therapeutics, Emeryville, CA) for 3-5 days.
  • PBMC Peripheral blood mononuclear cells
  • Non-adherent cells were collected after incubating the PBMC in DME medium containing 0.2% BSA at 37°C, 5% CO 2 for 2h.
  • the lymphocytes were cultured in RPMI 1640 medium
  • PBL peripheral blood lymphocytes
  • Example 4 Binding of the BsMoI to SCLC and T cells
  • the binding profile of the BsMoI and unconjugated OKT3 to four SCLC cell lines (H345, H69, SHP77, and DMS273) and peripheral blood mononuclear cells (PBMC) was analyzed by flow cytometry.
  • a mouse IgG2a was used as a negative control.
  • SCLC cells were pre-incubated with free BN, free Antag2, or a non-relevant peptide (angiotensin) at 10 uM before adding the BsMoI.
  • the cells were stained with the BsMoI using an indirect immunofluorescence staining method as described in Zhao et al., 2003.
  • the BsMoI binds to the four SCLC cell lines (black line in Panels A-D), while the unconjugated OKT3 does not bind to SCLC cells (grey line in Panels A-D).
  • the BsMoI binds to peripheral blood lymphocytes (Panel A), but does not bind to peripheral blood monocytes (Panel B).
  • the binding of BsMoI is specific and can be partially blocked by pre-incubating SCLC cells with either a free BN (Panel A) or a free Antag2 (Panel B), but is not blocked by a non-relevant peptide angiotensin (Panel C).
  • the BsMoI bound to peripheral blood lymphocytes (PBL) as well as the unconjugated OKT3, suggesting that the chemical conjugation process did not interfere with the biologic function of the 0KT3.
  • Example 5 Effect of Exemplary BsMoI and T Cells on Cancer Cells at
  • Example 6 Further Experiments on Effect of BsMoI on SCLC Growth
  • T lymphocytes were separated from the peripheral blood of healthy donors and cultured in media containing IL-2 (100U/ml) prior to experiments.
  • T cells effector cell, E
  • SCLC cells target cell, T
  • E effector cell
  • T target cell
  • the cell mixture was cultured for 4-72h. Controls included SCLC cells alone and T cells alone with or without the BsMoI.
  • DMS273 cells were added to each of the four donor samples, and the cells were cultured alone, in the presence of OK.T3 antibody, or in the presence of the OKT3xAntag2 BsMoI.
  • the results of the proliferation assay, indicated as percent inhibition of growth, are depicted in Figure 8. More specifically, the figure shows that, in all four donor samples, proliferation of the added DSM273 cancer cells was inhibited by the OKT3 antibody, but that the inhibition was significantly enhanced by fusion of the Antag2 antagonist to the 0KT3 antibody (i.e., by the OKT3xAntag2 molecule).
  • ADCC antibody-dependent cellular cytotoxicity
  • T cell proliferation was measured by a standard thymidine incorporation assay. Fresh PBL (2.5x10 4 /well) were seeded into a 96-well microplate and cultured for 72h, with either unconjugated OKT3, the BsMol, or a control antibody mouse IgG2a. IL-2 at 100 units/ml was added in the culture for 72h. Cells were harvested by a Tomtec cell harvester (Perkin-Elmer, Downers Grove, IL) and counted in a liquid scintillation counter. All assays were performed in triplicate.
  • PBL separated from normal donors consisted of more than 80% T cells.
  • the immunophenotype of these cells was: 81 ⁇ 7% positive for CD3, 52 ⁇ 13% positive for CD4, 34 ⁇ 10% positive for CD8, 17 ⁇ 6% positive for CD56, 8 ⁇ 4% positive for CD25, and 19 ⁇ 11% positive for CD69.
  • the cell viability was greater than 90%.
  • CPM -Thymidine incorporation
  • DMS273 cells and H345 cells were cultured with T cells (E:T ratio 1 : 1) and the exemplary BsMoI or a control antibody for 4-24 hours.
  • Annexin V expression (as an indicator of apoptosis)
  • propidium iodide (PI) staining were analyzed by flow cytometry. Briefly, SCLC cells were mixed in a 96-well plate with T cells at an E:T ratio of 5:1 to 1 : 1 in the presence of the BsMoI or mouse IgG2a and cultured for 4h and 48h.
  • SCLC cells were washed and immediately stained with annexin V-FITC, propidium iodide (PI), and anti-CD45-FITC. All samples were acquired at 10,000 events for each sample by flow cytometry and analyzed by Cellquest software. SCLC cells were identified as CD45-FITC negative cells (dark black dots). T cells were identified as CD45-FITC positive cells (grey dots). Apoptotic SCLC cells were identified as annexin V-positive/PI-negative cells, while necrotic SCLC cells were identified as Pl-positive/annexin V-negative cells.
  • T cells accounted for 66% of the cells at time zero (E:T ratio of 2:1), and decreased to 40% at 48h, while the DMS cells accounted for 34% of cells at time 0, and increased to 60% at 48h. This dynamic change is correlated with an increased expression of Bcl-2 in DMS273 cells.
  • H345 cells were more susceptible to cytotoxicity, as shown in Figure 1 IA.
  • the apoptotic cell population increased from 12% at 4h to 32% at 48h.
  • the necrotic cell population increased from 14% at 4h to 20% at 48h.
  • the live H345 cell population decreased from 50% at baseline (E:T ratio of 1 : 1) to 31 % at 4h, and 6% at 48h of the cytotoxicity assay.
  • the T cells accounted for 50% of cells at time zero, and remained stable about 42% at 48h. This was also correlated with a decreased expression of Bcl-2 protein at 48h of the cytotoxicity assay in H345 cells.
  • FIG. 12A-C A summary of flow cytometry analysis of four ADCC assays is presented in Figures 12A-C. The summary of flow cytometry analysis using T cells from four different donors is presented as mean ⁇ SD. After a 24h ADCC assay, there was a significant increase in both apoptosis and necrosis of SCLC cells in the presence of the BsMoI when compared to a control antibody, The E:T ratio in these experiments was 1:1 for H345 (Panel C) cells and 2:1 for DMS273 (Panel A) and SHP77 (Panel B) cells.
  • apoptosis is one of the important mechanisms in BsMol-mediated cytotoxicity, and that the BsMoI is capable of inducing apoptosis at a low E:T ratio. This observation is most relevant in the clinical setting, wherein the E:T ratio is usually low at the actual tumor site.
  • Figure 13 shows the results of a second set of assays.
  • T cells from four donors were individually tested for release of IFN ⁇ after culturing in the presence of BsMoI and H345 cells, DMS273 cells, H69 cells, or no SCLC cells.
  • Figure 13 shows that at a high E:T ratio of 20:1, BsMoI significantly increases IFN ⁇ release from the T cells.
  • BsMoI or OKT3 but no target cells
  • Bcl-2 and Bcl-xL have anti- apoptotic function through maintenance of mitochondrial membrane permeability and inhibition of Cytochrome C release.
  • Bak and Bax have pro-apoptotic functions, which operate in both the mitochondrial and endoplasmic reticulum, and directly control Cytochrome C release leading to activation of caspases (mitochondrial mediated apoptosis pathway).
  • Bad is a pro-apoptotic member that binds to Bcl-2 and Bcl-xL to promote cell apoptosis.
  • Bcl-2 family proteins play a critical role in the regulation of apoptosis.
  • the anti-apoptotic protein Bcl-2 is expressed in 75% of SCLC.
  • BsMoI bispecific molecule
  • 0KT3 anti-CD3 antibody conjugated with a bombesin antagonist
  • E:T effector to target
  • T lymphocytes were separated from healthy donors.
  • SCLC cells were mixed with T lymphocytes at 1 : 1 ratio in the presence of the BsMoI or mouse IgG2a as a negative control.
  • the mixed cells were stained with annexin V, CD45, and propidium iodide (PI), analyzed by flow cytometry from 4h to 72h.
  • Whole cell lysates were prepared at 24, 48, and 72h, and analyzed for expression of Bcl-2, Bad and phosphorylated Bad (Serl 12), Bax, Bak, and cleaved poly(ADP-ribose) polymerase (PAKP) by Western blot.
  • caspase 9 is the only initiator caspase in the mitochondrial pathway. Once activated, the protein cleaves and activates downstream effector caspases, such as caspase 3 (CASP3), caspase 6, and caspase 7, which then cleave a number of cytoskeletal and nuclear proteins, such as PARP.
  • PARP is a key enzyme involved in DNA repair, replication, and transcription.
  • DMS273 or H345 cells were mixed with T cells at 2: 1 to 1 : 1 ratio with or without the BsMoI in a 96-well microplate. After culturing for 48h, cells were washed three times, centrifuged, collected, and transferred to a microfuge tube. Whole cell lysates were prepared from cell pellets as described in Zhao et al., 2003. The protein content in the whole cell lysate was determined. 40ug of protein was loaded to each lane of 10% and 12% SDS-poly-acrylamide gel. After electrophoresis, the gel was transferred to a nitrocellulose membrane.
  • the full-length as well as the cleaved CASP3, CASP9, and PARP were measured by an Apoptosis Sampler Kit (Cell Signaling Inc, Beverly, MA), according to the manufacturer's instructions. The signals were detected by exposing the membrane to a Kodak film after incubating the membrane with chemiluminescent reagent (Pierce Chemical Co. Rockford, IL). [126] At baseline, all four SCLC cell lines express the full-length CASP3 (35kDa) and PARP (116kDa), with no detectable expression of a cleaved CASP3 (17- 19kDa) and full-length CASP9.
  • a cleaved PARP (89kDa) is detected in all four SCLC cell lines in the presence of the BsMoI (Lane 2), while no cleaved PARP is detected with a control antibody (Lane 1).
  • the signal of a cleaved PARP in the presence of the BsMoI is the most intense one, and the signal of a full-length PARP nearly disappears.
  • a cleaved CASP3 (17kDa) is also detected in all four SCLC cell lines in the presence of the BsMoI. In DMS273 cells, there is again no detectable full-length CASP3 in the presence of BsMoI.
  • Example 13 In vivo Study of the Effect of the BsMoI Based Immunotherapy in a SCLC Xenografted SCID Mouse Model
  • the above described experiments showed that the BsMoI of Example 1 is an effective molecule for activating T cells and causing cell death of SCLC cells in vitro.
  • a mouse model was used. The results presented in this Example show that the BsMoI has in vivo activity that is correlated with its in vitro activity shown above.
  • the human SCLC xenograft model was established in our laboratory (Zhao, et al, 2003). Briefly, 10- to 12-week old NOD. CB 17-Prkdcf cid , abbreviated as NOD/Prkdc SCID, mice were obtained from Jackson laboratory (Bar Harbor, ME). The NOD/Prkdc SCID mice were injected with 1x10 6 DMS273 cells intraperitoneally (ip) six hours after a whole body irradiation of 35OcGy. The control mice received only DMS 273 cells at day 1. The treated mice then received either 5x10 6 BsMoI- armed T cells or OKT3-armed T cells on day 3 and day 10 ip. This model was used not only to show effectiveness of the BsMoI in treating tumors in vivo, but also to establish the treatment schedule, dose of human T cells, and to evaluate tumor size as the treatment results.
  • T lymphocytes were isolated from an unselected healthy donor and cultured with 100U/ml of IL2 for 3-10 days.
  • T cells Prior to injection, T cells were incubated (armed) with either the BsMoI (lug per IxIO 7 cells) or OKT3 (lug per IxIO 7 cells) for 20 minutes. The cells were washed to remove the excess BsMoI or OKT3, re-suspended to 5x10 6 per 0.3 ml PBS for the injection.
  • One group of mice received the BsMol-armed T cells, and the other group of mice received OKT3-armed T cells.
  • mice were injected with 5x10 6 T cells intraperitoneally on three different days.
  • each mouse was injected with 5x10 6 cells intraperitoneally on two different days (day 3 and day 10).
  • Mice were examined daily for general health, activity, sign of illness, and visible tumor growth. In experiment 1, mice were sacrificed at day 20 and 30. In experiment 2, mice were sacrificed at day 40. By day 40, the control mice had usually developed a significant tumor burden with clinical signs of illness. Sacrificed mice from both experiments had their peritoneal cavities washed with 5ml PBS to collect peritoneal exudate cells (PEC).
  • PEC peritoneal exudate cells
  • PEC from each mouse were counted and stained with anti-human CD45-FITC (marker for T cells), anti-human CD56-PE (marker for DMS273 cells), and anti-mouse CD45-PE.
  • AU data were acquired and analyzed by flow cytometry.
  • Peritoneal suspension tumor cells were calculated as: PEC count x % of human CD56+/human CD45-. After the wash, the peritoneal cavity was opened and carefully examined. All visible tumors were dissected and collectively weighed for each mouse. The student t-test was used to compare two groups of samples. The significance level was determined when p value was ⁇ 0.05 by two-sided analysis. The results are shown in Table 1, in which the results are presented as mean ⁇ SD.
  • the table shows that the development of solid tumors and peritoneal suspension tumor cells in mice treated with the BsMol-armed T cells was delayed and significantly reduced at 40 days.
  • the overall tumor burden was estimated by gross tumor weight and the number of peritoneal exudate tumor cells (PET).
  • PET peritoneal exudate tumor cells
  • the control mice all developed visible tumors earlier compared with the experimental mice. Some control mice had clinical signs of jaundice, anemia, and weight loss. All experimental mice that received either OKT3-armed or the BsMol-armed T cells showed no clinical signs of jaundice, anemia, or weight loss.
  • Example 14 Expression of Target Proteins on T Cells [135]
  • the above Examples show that a bi-specific molecule that targets SCLC and T cells, via CD3 on the T cell surface, is effective in vitro and in vivo for inhibition of SCLC cell growth and proliferation.
  • the invention also encompasses bi- specific molecules that target other cell surface proteins on aberrant cells and on T cells.
  • the various different T cell surface receptor targets were identified from T cells collected as described above.
  • T cells from four donors were incubated with IL-2 for 3- 5 days, then assayed with antibodies specific for the following cell surface receptors: CD3, CD4, CD8, and CD56.
  • the results of the assays are shown in Table 2.
  • Table 2 shows that the donor samples all included significant expression of not only CD3, but also CD4 and CD8. Additionally, more than 10% of the cells from some donors expressed CD56.
  • Table 2 shows that the donor samples all included significant expression of not only CD3, but also CD4 and CD8. Additionally, more than 10% of the cells from some donors expressed CD56.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des molécules thérapeutiques bispécifiques qui ciblent à la fois des cellules aberrantes, comme des cellules cancéreuses, et des cellules T. L'invention concerne également des compositions les comprenant. L'invention concerne en outre des procédés de détection de cellules aberrantes et des méthodes pour traiter des sujets atteints d'un ou de plusieurs cancers. Les molécules bispécifiques de l'invention se fixent à la fois sur les cellules T et sur les cellules aberrantes cibles, les amenant ainsi à se trouver en voisinage proche mutuel, de sorte que les effets de la cellule T puissent être aisément localisés sur la cellule aberrante cible.
PCT/US2005/047222 2004-12-30 2005-12-29 Molecule bispecifique comprenant un ligand pour une proteine de surface et un ligand pour une proteine de surface de cellules t Ceased WO2006073982A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64005804P 2004-12-30 2004-12-30
US60/640,058 2004-12-30

Publications (2)

Publication Number Publication Date
WO2006073982A2 true WO2006073982A2 (fr) 2006-07-13
WO2006073982A3 WO2006073982A3 (fr) 2007-06-14

Family

ID=36648040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047222 Ceased WO2006073982A2 (fr) 2004-12-30 2005-12-29 Molecule bispecifique comprenant un ligand pour une proteine de surface et un ligand pour une proteine de surface de cellules t

Country Status (1)

Country Link
WO (1) WO2006073982A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074865A1 (fr) * 2006-12-21 2008-06-26 Novo Nordisk A/S Ligands des récepteurs de la prolactine dimères
EP2392671A1 (fr) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Procédé d'identification si un patient est réactif ou non à l'immunothérapie basé sur l'expression différentielle du gène CD3D
CN115304680A (zh) * 2022-03-11 2022-11-08 四川大学华西医院 基于Pep42构建的双特异性细胞接合器分子的制备及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUM L.G. ET AL.: 'Phase I/II Study of Treatment of Stage IV Breast Cancer with OKT3 x Trashuzumab-Armed Activated T Cells' CLINICAL BREAST CANCER vol. 4, no. 3, August 2003, pages 212 - 217, XP008081778 *
ZHOU J. ET AL.: 'Bombesin/Gastrin-Releasing Peptide Receptor: A Potential Target for Antibody-Mediated Therapy of Small Cell Lung Cancer' CLINICAL RESEARCH vol. 9, 15 October 2003, pages 4953 - 4960, XP003013773 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392671A1 (fr) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Procédé d'identification si un patient est réactif ou non à l'immunothérapie basé sur l'expression différentielle du gène CD3D
WO2008074865A1 (fr) * 2006-12-21 2008-06-26 Novo Nordisk A/S Ligands des récepteurs de la prolactine dimères
CN115304680A (zh) * 2022-03-11 2022-11-08 四川大学华西医院 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
WO2023169583A1 (fr) * 2022-03-11 2023-09-14 四川大学华西医院 Préparation et application d'une molécule d'engagement de cellule bispécifique construite sur la base de pep42
CN115304680B (zh) * 2022-03-11 2024-02-02 四川大学华西医院 基于Pep42构建的双特异性细胞接合器分子的制备及其应用

Also Published As

Publication number Publication date
WO2006073982A3 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
ES2954851T3 (es) Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
JP7391510B2 (ja) ヒト化抗ｃｄ７３抗体
US11964015B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
JP2022068296A (ja) 抗ｃｄ１１２ｒ組成物及び方法
CN112533944A (zh) 多特异性结合蛋白及其改进
CN111094345A (zh) 具有人结构域的抗b细胞成熟抗原嵌合抗原受体
Ferluga et al. Simultaneous targeting of Eph receptors in glioblastoma
US8425906B2 (en) Method to inhibit cancer targeting CD24
EP2428252B1 (fr) Neutralisation de l'invasion de blocs d'activité CD95 dans des cellules de glioblastome in vivo
US11788093B2 (en) Chimeric antigen receptor t-cells expressing interleukin-8 receptor
JP2024509258A (ja) 免疫細胞会合タンパク質と免疫調節薬を用いる併用療法
CN110494152B (zh) 短trail抗体及使用方法
EP3068797B1 (fr) Constructions de ciblage multivalent de tumeurs
JP2023508047A (ja) Ｉｌ－２受容体作動薬及び免疫チェックポイント阻害薬を使用する併用療法
KR20210131387A (ko) 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
US20180057603A1 (en) Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
EP3030268B1 (fr) Combinaison d'ifn-gamma et d'anticorps anti-erbb pour le traitement de cancers
CN114746106A (zh) 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法
Zhou et al. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes
WO2006073982A2 (fr) Molecule bispecifique comprenant un ligand pour une proteine de surface et un ligand pour une proteine de surface de cellules t
JP7561631B2 (ja) 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
CA3122421A1 (fr) Cellules car-t psca
KR102739632B1 (ko) 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
US20220401753A1 (en) Methods of increasing response to cancer radiation therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05855733

Country of ref document: EP

Kind code of ref document: A2